Two of the simplest ways to measure the success of companies that develop and commercialize drugs is to count their approvals ...

In a report released yesterday, Florent Cespedes from Bernstein maintained a Buy rating on Novartis AG (NOVN – Research Report), with a ...

Novartis presented updated Phase III NATALEE trial results at ESMO 2024, showing that Kisqali (ribociclib) with endocrine ...

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell ...

Vadodara: Alembic Pharma has announced that Sudhakar Pandiyan has been appointed as Head - Technical Operations (Sterile & ...

Analyst Etzer Darout of BMO Capital maintained a Hold rating on Novartis (NVS – Research Report), retaining the price target of $118.00.

Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.

Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors Lugano, Switzerland – September 19, 2024 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over ...

In 2022, the global oncology market was valued at approximately $203.42 billion and is expected to reach over $470.61 billion ...

NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...